Cyclo Therapeutics (CYTH) Reports Publication of Data from Phase 2 Study of Trappsol Cyclo streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Data published in official journal of Molecular Genetics and Metabolism Reports:
Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion
Trappsol® Cyclo™ was detected in the CSF
Completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale (17D-NPC-CSS)
Improvement in Scale Assessment and Rating of Ataxia (SARA) score for the mean score in 7 of 8 domains at Week 48 compared with baseline
Demonstrated a favorable benefit-risk profile
TOPEKA – The Kansas Department for Children and Families (DCF) recently joined the National Child Welfare Workforce Institute’s Breakthrough Series Collaborati
Cyclo Therapeutics (CYTH) Provides Clinical Program Update and Highlights Recent Achievements streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
18.10.2022 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, . Seite 1